Promega Executive and Leadership Team

Les Louia, the President & Chief Executive Officer at Promega, directs the overarching corporate strategy for biotechnology manufacturing. Overseeing the development of enzymes and molecular biology tools, the President & Chief Executive Officer ensures alignment between research innovation and market demand. This leadership role involves managing complex supply chains and scaling production capabilities to support global genomics and cellular analysis initiatives. By optimizing operational efficiency, Les Louia directly impacts the company's ability to provide critical reagents for drug discovery. The President & Chief Executive Officer maintains rigorous quality standards across all product lines, ensuring that the biotechnology portfolio meets the evolving needs of the scientific community. Through consistent focus on technical excellence and market expansion, Louia secures the long-term competitive position of the organization within the highly specialized molecular biology sector.

William Linton, the Chairman, Chief Executive Officer & President at Promega, architects the long-term vision for the organization. Focusing on the intersection of protein analysis and genetic identity, the Chairman, Chief Executive Officer & President drives the research and development agenda to maintain industry leadership. This role involves fostering a culture of scientific inquiry while overseeing the strategic deployment of resources across international markets. By championing innovation in cellular analysis, William Linton ensures that the company remains at the forefront of molecular biology advancements. The Chairman, Chief Executive Officer & President coordinates with the board to evaluate emerging technologies and potential market opportunities. Through sustained investment in core biotechnology platforms, Linton strengthens the company's reputation for reliability and precision, ultimately supporting the global scientific community in achieving breakthroughs in drug discovery and genomic research.

Deanna Schuppel, the Senior Executive Administrator, Chief Executive Officer at Promega, manages the executive office operations and internal governance frameworks. Coordinating high-level administrative functions, the Senior Executive Administrator, Chief Executive Officer facilitates communication between the leadership team and departmental heads to ensure operational cohesion. This role involves streamlining internal processes to support the manufacturing of biotechnology products and molecular biology tools. By optimizing executive workflows, Deanna Schuppel enhances the efficiency of strategic decision-making processes. The Senior Executive Administrator, Chief Executive Officer monitors organizational performance metrics to ensure alignment with corporate objectives in genomics and protein analysis. Through meticulous oversight of administrative systems, Schuppel supports the broader mission of the company, enabling the leadership team to focus on scaling production and expanding the reach of the biotechnology portfolio across diverse global research environments.

Chris Yarbro, the Chief Financial Officer at Promega, manages the fiscal health and capital allocation strategies for the biotechnology enterprise. Overseeing financial planning and analysis, the Chief Financial Officer ensures the availability of resources for research and development in genomics and protein analysis. This role involves monitoring global market trends to optimize revenue streams and cost structures across international operations. By maintaining rigorous financial controls, Chris Yarbro supports the sustainable growth of the company's manufacturing capabilities. The Chief Financial Officer collaborates with other executives to evaluate investment opportunities in new drug discovery technologies and cellular analysis platforms. Through strategic budgeting and risk management, Yarbro ensures the long-term financial stability of the organization. This leadership role remains vital for balancing the costs of high-precision manufacturing with the need for continuous innovation in the competitive molecular biology market.

Kristen Yetter, the General Manager and President at Promega, oversees the operational execution and regional performance of the biotechnology manufacturing business. Directing the day-to-day activities of key production units, the General Manager and President ensures that the company's portfolio of enzymes and molecular biology products meets quality and delivery targets. This role involves managing cross-functional teams to streamline manufacturing processes and enhance operational efficiency. By focusing on regional market requirements, Kristen Yetter drives the implementation of localized strategies that support global growth in genomics and cellular analysis. The General Manager and President coordinates with the executive team to align operational output with broader corporate objectives. Through proactive management of resources and personnel, Yetter maintains the high standards of excellence required in the biotechnology sector, ensuring that the company remains a trusted partner for researchers worldwide.

Brian Schiro, the Chief Information Officer at Promega, directs the digital infrastructure and data management strategies essential for biotechnology manufacturing. Overseeing the integration of advanced information systems, the Chief Information Officer ensures secure and scalable data handling for genomics and drug discovery research. This role involves implementing robust cybersecurity protocols to protect proprietary molecular biology data and intellectual property. By modernizing the technological landscape, Brian Schiro enables seamless collaboration across global research teams and manufacturing facilities. The Chief Information Officer manages the digital transformation of supply chain logistics, ensuring real-time visibility into product distribution. Through the deployment of sophisticated analytics tools, Schiro supports data-driven decision-making across the organization. This leadership role remains critical for maintaining the integrity of the company's digital assets while fostering innovation in the rapidly evolving field of molecular biology and cellular analysis.

Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, directs the commercial strategy and market expansion efforts for the biotechnology portfolio. Overseeing global sales teams, the Global Chief Revenue Officer, Strategic Business Lead drives the adoption of genomics and protein analysis products across diverse research sectors. This role involves identifying emerging market opportunities and tailoring business development initiatives to meet the specific needs of drug discovery clients. By optimizing the sales funnel and customer engagement strategies, Kara Machleidt ensures consistent revenue growth in both established and developing regions. The Global Chief Revenue Officer, Strategic Business Lead coordinates with product development teams to align commercial offerings with scientific advancements. Through strategic partnerships and market penetration efforts, Machleidt strengthens the company's presence in the global molecular biology industry, ensuring that innovative solutions reach researchers effectively.

Ash Anderson, the Chief Medical Officer at Promega, leads the clinical and medical strategy for the company's biotechnology applications. Overseeing the integration of molecular biology tools into clinical research and drug discovery workflows, the Chief Medical Officer ensures that products meet the highest standards of scientific and medical utility. This role involves collaborating with regulatory bodies and research institutions to validate the efficacy of genomics and cellular analysis solutions. By providing medical oversight, Ash Anderson guides the development of products that address critical challenges in genetic identity and disease research. The Chief Medical Officer monitors clinical trends to inform the product roadmap and ensure alignment with global healthcare needs. Through rigorous scientific evaluation and medical leadership, Anderson supports the company's mission to provide reliable, high-impact tools that advance the understanding of complex biological systems and improve research outcomes.